Format

Send to

Choose Destination
Curr Opin Ophthalmol. 2011 May;22(3):185-9. doi: 10.1097/ICU.0b013e3283459724.

Update on nonsurgical therapy for diabetic macular edema.

Author information

1
Wills Eye Institute, Retina Service, Philadelphia, Pennsylvania, USA. Ajwitkin@gmail.com

Abstract

PURPOSE OF REVIEW:

Treatment for diabetic macular edema (DME) is continuously evolving. While focal laser photocoagulation remains the standard of care, a new wave of studies is emerging that shows benefit of adjunctive therapy for DME.

RECENT FINDINGS:

With the advent of intravitreal corticosteroid and antivascular endothelial growth factor medications, new interest in the treatment of DME has been piqued, and a number of clinical trials have been designed to evaluate these therapies.

SUMMARY:

The goal of this article is to briefly summarize recent data from these trials, in order to aid the clinician in evaluating the most appropriate and up-to-date nonsurgical management options in treating diabetic macular edema. The key points are to summarize the most recent peer-reviewed literature regarding therapy for diabetic macular edema. Particular attention is paid to focal laser, corticosteroid, and anti-VEGF therapies.

PMID:
21427573
DOI:
10.1097/ICU.0b013e3283459724
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center